E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Adult patients with moderate to severe inflamed candidiasis of the skin |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 8.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10040809 |
E.1.2 | Term | Skin candida NOS |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
Difference of sum score of the clinical parameters dysesthesia/burning, erythema, pustules/vesicles, exsudation, maceration and extension from first visit (day 0) to main visit (day 3) |
|
E.2.2 | Secondary objectives of the trial |
- course of the clinical parameters dysesthesia/burning, erythema, pustules/vesicles, exsudation, maceration and extension individually and as sum score from the first visit (day 0) to the last visit - portion of patients with clinical and mycological successful treatment on day 14 and 21 - portion of patients with just clinical successful treatment on day 14 and 21 - portion of patients with just mycological successful treatment on day 14 and 21 - portion of patients with a relapse - globale evaluation of therapy success by the patient throughout the study course - globale evaluation of therapy success by the investigator throughout the study course |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- women and men aged between 18 and 65 years - written informed consent of patient - current diagnosis of candidiasis of the skin, proven with a positive mycological smear with at least a moderate amount of candida inside - parametes erythema and exsudation at least moderate - clinical parameters dysesthesia/burning, erythema, pustules/vesicles, exsudation, maceration and extension reach a sum score of at least 10 |
|
E.4 | Principal exclusion criteria |
- topical treatment of the investigation site with antimycotics and/or glucocorticoids less than 7 days prior to study entry - systemical treatment with antimycotics and/or glucocorticoids less than 4 weeks prior to study entry - known hypersensitivity to nystatine, hydrocortisone (acetate), zinc oxide or any other ingredients of the study medication - severe cardiovascular insufficiency, severe liver and renal insufficiency, severe respiratory insufficiency, neoplasm - severe acute or chronic concomitant disease with strong reduction of general condition - concomitant diseases which can influence the clinical parameters in a way that an objective assessment is inpossible - concomitant medication which can influence the methods of measurement or measurement results in a way, that an objective assessment is inpossible - confirmed doubts towards the cooperation of the patient - dementia or other intellectual impairment - history of alcohol and/or drug and/or substance and/or nicotine abuse -participation in another clinical trial less than 30 days prior to study entry or during this study - participation in this study before - female patients: pregnancy or lactation |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Reduction of inflammation, measured by the sum sore of the parameters dysesthesia/burning, erythema, pustules/vesicles, exsudation, maceration and extension from visit 1 (day 0) to main visit (day 3)
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
show the profit of hydrocortisonacetat |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | No |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | No |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | Yes |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | Yes |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | No |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | Yes |
E.8.1.5 | Parallel group | Yes |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Yes |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 6 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 6 |
E.8.9.1 | In the Member State concerned days | |